Skip to content
Sign In

Main Navigation

James Sharp Logo
  • Individuals
    Individuals

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service
  • Charities & Trustees
    Charities & Trustees

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • Companies
    Companies

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • News & Insights
    • News & Insights
    • Current Research Coverage List
  • About Us
    • About Us
    • Our People
  • Conectus Portal
  • Contact Us

Update - Page 3

29 April 2026

Coca-Cola Reports First Quarter 2026 Results

Coca-Cola Reports First Quarter 2026 Results and Updates Full Year Guidance Global Unit Case Volume Grew 3% Net Revenues Grew 12%; Organic Revenues (Non-GAAP)…

29 April 2026

Visa – Q2 2026 Results

Visa Reports Fiscal Second Quarter 2026 Results San Francisco, CA, April 28, 2026 – Visa (NYSE: V) Ryan McInerney, Chief Executive Officer, Visa, commented…

28 April 2026

GSK – Bepirovirsen Update

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA GSK plc (LSE/NYSE: GSK) today announced that the US Food…

28 April 2026

AstraZeneca – Breztri Update

Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older Approval based on KALOS…

27 April 2026

GSK – AnaptysBio Inc Litigation Update

TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation GSK plc (LSE/NYSE: GSK) subsidiary, TESARO, Inc., confirms that the Delaware Chancery Court has…

27 April 2026

Harworth and Microsoft Receive Resolution to Grant

HARWORTH GROUP PLC (‘Harworth’ or the ‘Group’ or the ‘Company’) Harworth and Microsoft receive resolution to grant planning consent for hyperscale data centre and…

27 April 2026

AstraZeneca – Saphnelo Update

Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus First-in-class Saphnelo Pen now offers greater flexibility and convenience,…

23 April 2026

Nestle Publish 2026 Three-Month Sales

Three-month sales 2026: continued growth momentum Philipp Navratil, Nestlé CEO, commented: “Our first-quarter performance demonstrates that our RIG-led growth strategy is delivering. Results were…

Posts navigation

  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 86
  • »

Home > Update > Page 3

James Sharp white Logo
Sign In
Linkedin Icon

The Exchange
5 Bank Street
Bury, Lancashire
BL9 0DN

Tel: 0161 764 4043

Fax: 0161 764 1628

Email: mail@jamessharp.co.uk

Linkedin Icon

James Sharp & Co is a trading name
of James Sharp & Co LLP (0C422665)

Members of the LLP are referred to as Partners

  • Downloads & Resources
  • Complaints
  • Financial Compensation Scheme
  • Conectus Portal

  • Cyber Essentials Certification
  • Website Terms & Conditions
  • Privacy Policy
  • Cookie policy
  • Consent Preferences

Email Newsletter Sign-up

Consent(Required)
What we do with you information. Find out more

© Copyright 2010-2026. All rights reserved. James Sharp & Co. Authorised & Regulated by the Financial Conduct Authority
Member of the London Stock Exchange - Member of the Aquis Stock Exchange - Member of PIMFA

Website by ICG